**Appendix Table C44. Treatment characteristics: Neuroblastoma**

| **Study (Investigator, country, year)** | **Dis-ease** | **Re-cord Num-ber** | **Group (N)** | **Stem Cell Source** | **Type of HSCT** | **Prior Treat-ment** | **Condi-tioning Regimen** | **Immunosuppressive therapy for GVHD prophylaxis** | **Supportive Care** | **Compara-tive Treatment** | **Comparative Treatment Dose/Regi-men** | **Com-ment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Berthold, Germany, 2005 | Neuroblastoma | 6760 | 149 | PBSC | single auto | 3 cycles of chemo (cisplatin and etoposide); vindesine; 3 cycles of vincristine and dacarbazine; ifosfamide; doxorubicin; radiotherapy; surgery | melphalan; etoposide; carboplatin; (dose and drug adjustments in 6 patients) | chimeric monoclonal antibody; retinoic acid after Nov 2002 | drugs given to control pain and allergic reactions during immunotherapy | maintenance chemotherapy | oral cyclophosphamide |   |
| George, USA, 2006 | Neuroblastoma | 5440 | 82 | PBSC | tandem auto auto | 5 cycles of chemo (multi-agents); surgery after 4th or 5th cycle; radiotherapy | high-dose chemo (etoposide, cyclophosphamide, carboplatin, melphalan); total body irradiation | 13-cis-retinoic acid |   |   |   |   |
| Hobbie, USA, 2008 | Neuroblastoma | 1690 | 13 | PBSC | tandem auto auto | 5 cycles of chemo; surgery after 4th or 5th cycle; radiotherapy | high-dose chemo (etoposide, cyclophosphamide, carboplatin, melphalan) and total body irradiation | 13-cis-retinoic acid |   |   |   |   |
| Kim, South Korea, 2007 | Neuroblastoma | 2870 | 36 | PBSC | tandem auto auto, 25%; single auto, 75% | 4-5 cycles of chemo (cisplatin, VP-16, doxorubicin, cyclophosphamide); surgery; radiotherapy and chemo | MEC (melphalan, etoposide, carboplatin), 65% (N=46 procedures); no total body irradiation | interleukin-2; 13-cis-retinoic acid |   |   |   | single-auto group consisted of CD34+ non-selected arm (n=13, 36%) and CD4+ selected arm (n=14, 39%) |
| Ladenstein, EGBMT, 2008 | Neuroblastoma | 1610 | 3350 | BM, 41%; 3%, BM+PBSC; PBSC, 56% (n=3295) | tandem auto auto, 14%; single auto, 86% | not specified1-4 cycles of chemo (various agents); surgery; radiotherapy; total body irradiation (33%) | busulfan; melphalan; cyclophosphamide; thiotepa; total body irradiation (14%, n=2,333)1-4 cycles of chemo (various agents); melphalan (81%); total body irradiation (34%) |   |   |   |   | auto-transplant group |
| Matthay, US, 2009; 1999 | Neuroblastoma | 6210 | 189 | BM | single auto | 5 cycles of chemo (cisplatin; doxorubicin; etoposide; cyclophosphamide); radiotherapy; surgery | carboplatin; etoposide; melphalan; total body irradiation | retinoic acid (n=50) | growth factors | conventional therapy | 3 cycles of cisplatin; etoposide; doxorubicin; ifosfamide; mesna |   |
| Pritchard, United Kingdom, 2005 | Neuroblastoma | 8030 | 32 | BM | single auto | vincristine; cyclophosphamide; cisplatin; teniposide; surgery (no radiotherapy) | melphalan |   | nutritional supplements | no further therapy |   |   |
| Sung, South Korea, 2007 | Neuroblastoma | 3950 | 52 | PBSC | tandem auto auto, 88%; single auto, 12% | 1997-2003: 5-7 cycles of chemotherapy; surgery; radiotherapy (if tumor remained post-surgery); 1-3 cycles of chemotherapy if no tumor or 3-5 cycles of chemo if tumor evident 2004-2005: 6 cycles of chemo; surgery; 3-4 cycles of chemo | 1997-2003: high-dose chemo 2004-2005: chemo and total body irradiation | 13-cis-retinoic acid and interleukin-2 |   |   |   |   |
| Sung, Korea, 2010 | Neuroblastoma | 2433 | 71 | PBC | Tandem | Induction and consolidation; total body irradiation | see Table 1 in article |   | 13-cis-retinoic acid; interleukin-2; local radiotherapy | Single | single PBC |   |